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IDENTIFICATION OF A SMALL MOLECULE INHIBITOR OF VIRULENCE 
FACTORS IN MULTIDRUG RESISTANT ACINETOBACTER BAUMANNII 
GEORGE DAVID KOSTIDES MASSEY 
ABSTRACT 
 Acinetobacter baumannii is an opportunistic pathogen prevalent in 
nosocomial infections, most commonly infecting humans with compromised 
immune systems during their hospital stays. The organism’s success in such 
circumstances has to do with its ability to survive on dry, abiotic surfaces (e.g. 
catheters, bed railings, and other medical equipment) and its increasingly 
apparent antibiotic resistance. These factors make A. baumannii a serious 
problem for healthcare professionals and in public health generally. A. baumannii 
is paradigmatic and representative of the issues confronting healthcare in the 
ongoing antibiotic crisis, and many strains are showing multidrug resistant (MDR) 
phenotypes. Given that the patients infected by A. baumannii tend to be very 
vulnerable and traditional antibiotic treatment seems to be getting less and less 
effective, it is imperative to explore alternative treatment options that may lead to 
better outcomes, especially if their mechanisms are not the same as the 
traditional antibiotics that exert the selective pressures that have led to the 
current antibiotic crisis. A small molecule called M64 is known to inhibit a LysR-
type transcription regulator (LTTR) important for virulence, but not cell growth or 
viability, in another opportunistic pathogen, Pseudomonas aeruginosa. The 
experiments presented here show that M64 was able to rescue mice infected 
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with A. baumannii and to downregulate the expression of important metabolic 
genes downstream from A. baumannii LTTRs BenM and CatM in vitro while 
having no effect on bacterial growth. BenM and CatM regulate genes involved in 
the metabolism of benzoate and catechol respectively, both of which are parts of 
tryptophan metabolism and are eventually broken down to form acetyl-CoA and 
succinyl-CoA for energy production in the citric acid cycle. Such a 
pharmacodynamic profile offers a starting point in the design of alternative 
treatments of MDR bacterial infections, as successful outcomes are observed 
without the direct killing of cells in vitro seen in traditional antibiotics. In this case, 
as catechol metabolism is important for siderophore biosynthesis and thus 
bacterial virulence, inhibition of the transcription of genes involved in catechol 
metabolism may be playing a role in the observed rescue of infected mice. 
Further studies are required to ascertain the nature of the inhibitor’s effect, 
however. 
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INTRODUCTION 
 
Acinetobacter baumannii 
A. baumannii was described as a distinct species within the genus 
Acinetobacter in 1986, when it was also noted that “[m]ost Acinetobacter strains 
isolated from human patients belong to this species” (Bouvet and Grimont, 1986). 
A. baumannii is increasingly being recognized as an important opportunistic 
pathogen in humans, especially in nosocomial settings (Scott et al., 2004; 
Pimentel et al., 2005; Geurrero et al., 2010). Immunocompromised patients have 
the highest risk of developing disease due to this opportunistic pathogen, and 
lethal cases have been described (Charnot-Katsikas et al., 2009; Ali et al., 2014; 
Sinha et al., 2014). Between 2002 and 2004, there was a notable rise in the 
number of cases of A. baumannii bloodstream infection seen in patients at US 
military medical facilities treating service members injured in Iraq, Kuwait, and 
Afghanistan (Scott et al., 2004), and occupational transmission of the bacterium 
from wounded military personnel to healthcare workers has been documented 
(Whitman et al. 2008). 
 The two most important features of A. baumannii that represent problems 
to healthcare are its increasing antibiotic resistance (Fournier et al., 2006; 
Maragakis and Perl, 2008; Gordon and Wareham, 2010; Castanheira et al., 
2014) and its ability to survive for long periods of time on dry, abiotic surfaces 
(Jawad et al., 1998), evidenced by surveillance culture results in hospitals where 
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outbreaks have occurred (van den Broek et al., 2006) and probably related to the 
bacterium’s marked ability to form biofilms (Longo et al., 2014). In turn, biofilm 
formation increases the persistence and antimicrobial resistance of the bacteria. 
Thus, A. baumannii colonization of surfaces in the hospital environment can pose 
very serious public health issues (Figure 1). It has also been included amongst 
the ESKAPE pathogens (Rice, 2008; Table 1), which are noted to be 
opportunistic pathogens that are highly resistant to currently available antibiotic 
treatments, presenting “new paradigms in pathogenesis, transmission, and 
resistance” (Dijkshoorn et al., 2007). As such, these bacteria pose particularly 
difficult challenges to investigators trying to develop the novel therapeutic options 
that are so desperately needed. 
Curiously, although A. baumannii may be the most common species of 
Acinetobacter isolated from humans, “the existing data indicate that A. baumannii 
has a low prevalence in the community and that its occurrence in the 
environment is rare” (Dijkshoorn et al., 2007). In 1968, unspeciated 
acinetobacters were isolated from soil and water samples (Baumann, 1968), 
while unspeciated clinical isolates were known even earlier, but Acinetobacter 
baumannii specifically has not been shown to be a commonly found soil 
bacterium. 
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Figure 1: Dynamics of bacterial transmission in a 
hospital environment, adapted from Dijkshoorn et al. 
2007. 
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Table 1: The ESKAPE Pathogens, as described by Rice (2008) 
Letter Bacterium 
E Enterococcus faecium 
S Staphylococcus aureus 
K Klebsiella pneumonia 
A Acinetobacter baumannii 
P Pseudomonas aeruginosa 
E Enterobacter spp. 
 
 
Some of the ESKAPE pathogens have been more thoroughly studied than 
others. For example, well-established model systems exist for studying P. 
aeruginosa in Drosophila (Apidianakis and Rahme, 2009) and in a variety of 
infection models in mice (Hoffmann et al., 2005; Kukavica-Ibrulj and Levesque, 
2008). On the other hand, in the case of A. baumannii, immunocompromised 
murine models are often employed (Harris et al., 2013; Thompson et al., 2014) 
and Galleria mellonella has been utilized as a non-vertebrate model organism 
(Peleg et al., 2009) while Drosophila models have not been described. 
Conveniently, for the studies described herein, several strains of A. 
baumannii were available in the lab, some being relatively well-established lab 
strains and others being newly-acquired clinical isolates from patients 
hospitalized at Shriner’s Hospital. This availability of several strains meant that 
studies could be broad enough to show potentially far-reaching effects that could 
be applied to yet other Acinetobacter strains or even species. 
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 The aforementioned Drosophila and murine infection models were also 
conveniently well-established and would offer a diversity of ways to study the 
available Acinetobacter strains, including the previously unstudied local clinical 
isolates shown below (Table 2). Reliable observation of virulent phenotypes 
(animal death) in infected flies or mice would allow for the screening of other 
strains for virulence, the testing of possible treatments to rescue infected 
animals, and analysis of bacterial proliferation in an in vivo setting. 
 
 
 
Table 2: Strains of A. baumannii available for study 
A. baumannii strain Source Notes 
Shriner’s Clinical (Shr 
Cl) strain 69 Shriner’s 
Hospitals for 
Children, Boston 
Local clinical isolates Shr Cl 70 
Shr Cl 71 
Shr Cl 72 
AYE VB-1 
Fournier et al., 
2006 
Multidrug resistant 
SDF Sensitive to antibiotics 
AB 5075 
Jacobs et al., 
2014 
Multidrug resistant; mutant 
library available 
ATCC 17978 ATCC 
Multidrug resistant; 
transposon library available 
 
 
Inhibitor M64 and its Action 
With an eye towards investigating potential treatments of A. baumannii 
infections, it was decided to explore the effects of a molecule recently found to 
disrupt bacterial quorum-sensing regulated pathogenicity in Pseudomonas 
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aeruginosa (Starkey et al., 2014) in experimental A. baumannii infections and in 
vitro. This molecule, termed M64 (Figure 2), presents great promise in treatment 
of P. aeruginosa infections because while it attenuates acute bacterial virulence 
and so increases the likelihood of host survival, it is not a classic antibiotic 
(targeting bacterial growth or cell viability, eg) and so does not kill cells directly. 
This means that P. aeruginosa is less likely to develop a resistance to this 
compound in the same way that bacteria develop resistance to classic antibiotics. 
Ultimately, such a strategy offers many advantages over classical antibiotics, as 
it could treat potentially lethal infections while sidestepping the current antibiotic 
resistance crises. If M64 shows similar or otherwise disruptive effects in 
experimental A. baumannii infections and cultures, it could prove an important 
first step towards the development of both next-generation antimicrobials and 
new treatment plans for human infection with this bacterium. 
 
Figure 2: M64, small molecule inhibitor of quorum-sensing regulated 
pathogenicity in Pseudomonas aeruginosa. Adapted from Starkey et al. 
2014. 
 7 
 
 
 In P. aeruginosa, M64 has been shown to inhibit a transcription factor 
known as MvfR (multiple virulence factor regulator), which ultimately regulates 
several functions related to the quorum-sensing regulated virulence of the 
pathogen but is not essential to cell viability (Starkey et al., 2014). Thus, targeting 
MvfR with a drug does not exert the same evolutionary pressure as classical 
antibiotics with their classic targets do, as cells are not being killed. Instead, an 
inhibitor of MvfR can inhibit pathogenicity by disrupting quorum-sensing 
regulated functions without outright killing of the pathogen: an infected patient 
treated with such a drug would see their symptoms alleviated while their own 
immune system eventually eradicates the pathogen itself. 
 It is important to note that MvfR is a LysR-type transcriptional regulator 
(LTTR), a class of regulators which “control the expression of a diverse array of 
virulence regulons in Gram-negative and Gram-positive pathogens, and are the 
largest family of homologous regulators in prokaryotes” (Starkey et al., 2014). 
This indicates that a promising potential starting point in investigating the effects 
of M64 on A. baumannii would be any known LTTRs present in that bacterium. 
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To be specific, two of the most studied LTTRs in A. baumannii are BenM 
and CatM, which are involved in the regulation of benzoate and catechol 
metabolism (Collier et al., 1998; Ezezika et al., 2006; Ezezika et al., 2007; Zhang 
et al., 2012). If M64 can be shown to have some disruptive effect on bacterial 
metabolism and if this metabolic defect is connected to less prominent virulence 
phenotypes, M64 could be a promising place to start in the investigation of non-
traditional antibiotic treatments of A. baumannii infection. 
 
Research Objectives and Project Outline 
 The overarching objective of the research project was to investigate the 
effects of M64 on A. baumannii. As the non-bactericidal M64 was known to inhibit 
virulence factors in P. aeruginosa by acting on MvfR, special attention early in 
the project was devoted to in vivo studies where animal models were used to test 
Figure 3: A simplified overview of quorum-sensing regulated pathogenicity 
in P. aeruginosa and the point of action of M64. 
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if M64 could rescue animals from what would otherwise be lethal infections. A 
decrease in virulent infection phenotypes in experimental groups receiving M64 
as treatment would provide a reason for further investigation of the effects of M64 
on A. baumannii. 
Growing A. baumannii in the presence and absence of M64 in different 
media yielded clues not only about the inhibitor’s effects on and potential targets 
in A. baumannii but also on relevant characteristics intrinsic to the bacterial 
strains in question that might explain the later observed in vivo phenotypes. 
When the in vitro studies seemed to show M64 interfering in certain aspects of A. 
baumannii metabolism, in vivo studies were attempted to inquire into the live anti-
virulence functions of the inhibitor. 
 
 10 
METHODS 
 
Bacterial Cultures 
 A sterile loop was used to scrape a 25% glycerol frozen (-80°C) bacterial 
stock. The loop was then dipped into 5 mL lysogeny broth (LB) in a culture tube, 
which was then set into an incubator at 37°C and 200 rpm shaking to allow the 
culture to grow overnight (16 hours), after which a 1:100 dilution (in LB) of the 
culture was grown over the course of the day (“overday” culture), in the same 
conditions. 
 Another medium used in some of the experiments was M63gcm, which 
was assembled as shown below (Table 3 and Table 4). Components were mixed 
via shaking or stirring in a sterilized bottle and the solution was then sterilized 
again via filtration into a new sterilized bottle. 
Chemical Quantity 
(NH4)2SO4 10 g 
KH2PO4 68 g 
FeSO4·7H2O 2.5 mg 
Deionized H2O 1 L 
Table 3: 1 L 5x M63 stock solution components 
 
Chemical Quantity 
5x M63 stock 100 mL 
Deionized H2O 382.5 mL 
20% glucose 5 mL 
20% w/v casamino acids 12.5 mL 
1M MgSO4·7H2O 0.5 mL 
Table 4: 500 mL 1x M63gcm working solution components 
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Assessments of Virulence/Animal Infections 
 Much insight into how virulent and in what ways A. baumannii can be 
virulent in humans can come from simply infecting animal model organisms and 
analyzing the results. Two animal models were attempted to study A. baumannii 
in vivo, one invertebrate and one vertebrate: Drosophila melanogaster and Mus 
musculus. 
Drosophila melanogaster 
 Drosophila infection was carried out as described previously for infection 
with P. aeruginosa (Apidianakis and Rahme, 2009). Five- to seven-day-old male 
wild type (Oregon-R) flies were selected for each experiment. Overday bacterial 
cultures were allowed to grow until reaching an optical density (600 nm; OD600nm) 
of 3.0. Aliquots were taken from this overday culture and centrifuged for three 
minutes at 8000 rcf. The supernatant LB was removed and the pelleted bacteria 
were resuspended in an equal volume of 10 mM MgSO4 to wash them. After 
repeating the centrifugation and removing this wash, the pelleted bacteria were 
again resuspended in an equal volume of 10 mM MgSO4 and this inoculum was 
considered ready for further dilution or experimental use. 
 Actual fly infection was carried out by dipping a disinfected needle into the 
inoculum and pricking flies, anesthetized with carbon dioxide, in the thorax. 
Infected flies were removed from anesthesia and put back into an incubator at 
21°C, where their survival could be monitored over time. Flies in the control 
groups were pricked with a needle dipped into plain 10 mM MgSO4. 
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 An alternative to the needle pricking experiment was the glass 
micropipette microinjection infection model. Both involved thoracic pricking of the 
flies, thereby modelling the infection in a physically traumatic case, but the 
microinjector allowed for more controlled doses of bacteria to be delivered at the 
site of the wound by determining the bacterial inoculum CFU/mL, since the 
microinjector delivers a user-defined volume of inoculum with each injection. For 
microinjector experiments, overday bacterial cultures were grown until reaching 
OD600nm 3.0. Aliquots of these cultures were centrifuged, supernatant LB was 
removed, and the cells were resuspended in 10 mM MgSO4. A new pulled glass 
micropipette was attached to the instrument for each experiment, and the pipette 
was filled with the bacterial inoculum. (Or plain 10 mM MgSO4 for control group 
injections.) 9.2 nL of solution were injected into each fly. 
 The third infection model tested was a non-traumatic gut infection model. 
In this assay, the control groups of flies were sorted into tubes where they were 
provided with 5 mL filter-sterilized 4% sucrose solution as food, pipetted onto 
sterile cotton balls at the bottoms of the tubes. Infection groups received 5-x mL 
of 4% sucrose solution and x mL of a bacterial overday culture that had been 
centrifuged, had the supernatant x mL LB removed, and the pelleted bacteria 
resuspended in x mL 4% sucrose. The sucrose solutions with and without 
bacteria were mixed together into a 5 mL solution and pipetted onto cotton balls 
at the bottoms of the tubes. The amount of bacterial inoculum x used could be 
tailored to provide the flies with any number of CFUs with their sucrose food, 
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though this experiment is inherently more variable, as it is somewhat difficult to 
control for the amount each fly may eat. In any case, the bacterial inoculum 
always came from an OD600nm 3.0 overday culture. 
Mus musculus 
 As mentioned before, mouse models had been widely employed in 
previous studies of A. baumannii (Luo et al., 2012; Lin et al., 2012; Jacobs et al., 
2014; Thompson et al., 2014). Part of the appeal of the mouse model is in how it 
lends itself to the study of various types of infections, including open wounds, 
burns, and septicemia (via intraperitoneal [IP] injection). Mice have also been 
used to study pneumonia secondary to lung infection (Joly-Guillou et al., 1997; 
Harris et al., 2013). Methods to immunocompromise mice, thus raising their 
susceptibility to infection and better representing the sickly patients most at risk 
of becoming infected with A. baumannii in hospitals, have also been described 
(Zuluaga et al., 2006; Manepalli et al., 2013). 
 It was decided to test the lung infection model using seven-week old male 
CD-1 mice (Charles River Laboratories, MA, USA). The mice were 
immunocompromised with two IP injections of cyclophosphamide in 0.9% NaCl 
saline, one dose (150 mg/kg) four days before infection and another dose (100 
mg/kg) the day before infection. Lung infection was accomplished via intranasal 
inoculation of 25 µL of 10 mM MgSO4 containing the desired amount of CFUs for 
testing. The bacteria came from aliquots from overday liquid cultures grown to 
OD600nm 2.0. The aliquots were centrifuged at 8000 rcf for three minutes, the 
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supernatant LB was removed, and the cells were resuspended and washed once 
with 10 mM MgSO4, followed by a second centrifugation at 8000 rcf for three 
minutes and resuspending in 10 mM MgSO4, with cells being diluted or 
concentrated as desired for testing. For the purposes of assessing CFUs from 
lungs or measuring lung weights, mice were sacrificed two days after infection at 
the earliest. Lung CFUs were measured by homogenizing the retrieved lung 
tissue in 1 mL PBS and plating serial dilutions of the resulting mixture on LB agar 
plates. 
 
Minimal Inhibitory Concentration (MIC) experiments 
Rich media 
  One night before the experiment, a sterile loop was used to scrape a 25% 
glycerol frozen bacterial stock of the strain(s) of interest and streak a LB agar 
plate. After 16 hours incubation at 37°C, isolated colonies were picked from the 
plates using a sterile loop. The colonies were immediately suspended in the 
medium being tested in the experiment via pipetting repeatedly and vortexing, 
with each strain’s newly-formed liquid culture then being appropriately diluted so 
that each culture featured a similar number of colony-forming units (CFUs) per 
mL. 
 The inhibitor of interest (M64) was serially diluted from a concentrated 
stock solution to achieve the final concentrations of inhibitor to be tested, taking 
into account that the inhibitor was to be further diluted when all the experimental 
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components were finally plated (below). With these dilutions, the experiment was 
controlled for the volume of inhibitor solvent (DMSO) placed in each well of the 
plate. 
 Finally, 100 µL of empty medium was placed in each well of a 96-well 
clear, sterile, round-bottom assay plate. In each column of wells, 6 µL of 
appropriately-diluted inhibitor was added. Across each row of wells, 100 µL of 
bacterial culture (suspended colonies) was added so that, across one row of the 
plate, different concentrations of inhibitor were present in each well with the 
same amount of bacteria. As a negative control, each row also featured one well 
with no inhibitor added but rather with 6 µL 0.1 mg/mL polymyxin B, an antibiotic, 
dissolved in water. The positive control in each row was one well with 6 µL of 
plain DMSO added without inhibitor or antibiotic. The OD600nm of each well was 
measured every 15 minutes by a Tecan Infinite 200 microplate reader 
(Männedorf, Switzerland) over the span of at least 24 hours. 
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Minimal media 
 Original experiments were entirely similar to the MIC experiments in rich 
media, only substituting the minimal medium M63gcm for bacterial culture 
dilutions and on the 96-well plate. Later experiments did not use isolated colonies 
from a streak plate but rather overday liquid cultures that had been allowed to 
grow to an OD600nm of 2.0 and which were then serially diluted to 1:1000. These 
1:1000 dilutions were used in the 96-well plate, meaning that the final amount of 
bacteria in each well amounted to approximately a 1:2000 dilution of an overday 
OD600nm 2.0 culture for each strain, accounting for the 100 µL of empty M63gcm 
media that was added to each well along with 100 µL of the 1:1000 diluted 
Figure 4: Setup of the 96-well plate for the MIC 
experiments 
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overday culture. The different tested concentrations of inhibitor M64 remained 
the same as in the rich media MIC experiments. 
 
qPCR 
 Real-time polymerase chain reaction (qPCR) was used to explore the 
effects of M64 on gene expression in A. baumannii. Overday liquid cultures were 
grown to the desired OD600nm, still in LB but this time also in the presence of 
either plain DMSO or 50 µM M64. Aliquots from these cultures were then used 
for RNA extraction and the subsequent steps. 
RNA extraction from the cells was achieved using the Qiagen RNeasy® 
Mini Kit and following the included instructions. Synthesis of cDNA from bacterial 
RNA was achieved using Invitrogen Superscript® III First-Strand Synthesis 
System (Thermo Fischer Scientific, MA, USA) and following the included 
instructions. The qPCR reactions were carried out using Brilliant II SYBR® Green 
QPCR Master Mix (Agilent Technologies, CA, USA) and following the included 
instructions, while the sequences of the primers used to amplify each gene are 
shown in Table 5 below. Primers for the 16S RNA were the same as used 
previously by Peleg et al., 2007. Primers for benA were the same as used 
previously by Zhan et al., 2009. The remaining primers were designed using the 
primer design tools available from the National Center for Biotechnology 
Information (NCBI). 
 
 18 
Gene Forward primer Reverse primer 
benM GACCAAGCGTATTGGTCTCA TCGAGGCAGCAACCCATAAA 
catM TTCGAAAAAGGCTCTCGTCC GCGTCAAAATTTGCACCGCA 
benA GGTGGCTCCTATGGCTTTGA TTTCGGTGTATTCATCTGCT 
benB AAGCCACAATATTGCCAACG CCAGTTAAAGCGAACAGTGAC 
catB CGTTCGGCACTGAATTAT GTAACGTAGCGGCTCTTTTA 
catC TTCCACTTGATATGCCAGCC TGTGACGCCATTTACCTTGG 
16S RNA CAGCTCGTGTCGTGAGATGT CGTAAGGGCCATGATGACTT 
Table 5: Primers used to amplify the ben and cat genes via qPCR. 
 
Statistical Analyses 
 Results from the mouse model pneumonia and infection studies were 
analyzed for statistical significance (P ≤ 0.05) using two-tailed t-tests (equal 
sample sizes, equal variance). Results from the qPCR gene expression studies 
were analyzed by computing the fold change in gene expression compared to 
16s ribosomal RNA and using a two-tailed t-test (equal sample sizes, equal 
variance) to check for a statistically significant (P ≤ 0.05) difference. Results of 
the killing kinetic study where one group was treated with M64 and one was not 
(Figure 8) were analyzed using the log-rank test. 
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RESULTS 
 
In vivo Experiments 
Drosophila melanogaster Infections 
 Early experiments involved attempts to establish a host-pathogen model 
system using D. melanogaster and A. baumannii. Such a system had not been 
previously described in the literature, but was convenient to attempt in the lab 
since the bacteria and the flies were both readily available. Many experiments 
with several different strains and modes of infection were attempted, but none 
showed any significant effects from bacterial infection in healthy, wild type 
(Oregon-R) flies. Infected flies, regardless of the number of CFUs used to infect, 
did not die any more quickly than their non-infected counterparts. A 
representative sample of this data is shown in Figure 5. 
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Mouse Infections 
 The immunocompromised mouse lung infection model provided reliable 
phenotypes indicative of bacterial-induced pneumonia, even in 
immunocompetent mice. Shriner’s Clinical Strain 69 was used to infect 
immunocompetent mice to see if the strain was virulent enough to kill mice. 
Although no immunocompetent mice succumbed to the infections, some indices 
provided evidence that the mice were coming down with pneumonia (Figures 6, 
7) despite a lack of cultivable CFUs in lung tissue from sacrificed mice. 
Figure 5: Survival of flies infected with A. baumannii strains via 
thoracic pricking. The positive control group were infected 
with PA14, a strain of P. aeruginosa known to be highly 
virulent in flies. 
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Figure 6: Weights of 
immunocompetent mice infected 
intranasally with Shr Cl 69, four days 
post-infection. Mice infected with a 
higher number of CFUs exhibited more 
weight loss, indicating some degree of 
sickness despite that no mortality was 
observed. 
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Figure 7: Indicators of pneumonia four 
days post-infection in immunocompetent 
mice infected intranasally with Shr Cl 69. 
Mice infected with a higher number of 
CFUs exhibited significantly greater raw 
lung weight and greater lung index (mg 
right lung tissue/g body weight), consistent 
with a more advanced case of pneumonia. 
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 A. baumannii was seen to be much more virulent in other experiments 
where the mice were immunocompromised using cyclophosphamide prior to 
inoculation. In these experiments, significant mouse mortality was observed 
(Figures 8, 9), and more concentrated inocula produced higher mortality (Figure 
8). 
  
Figure 8: Killing kinetic of immunocompromised mice infected 
intranasally with Shr Cl 69. (Infection occurred at t = 0) 
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 Shr Cl 69 was not the only strain that produced such a virulent phenotype 
in infected mice. AB 5075, a more established lab strain, was also tested and 
showed a high degree of virulence. Most importantly, significantly less mortality 
and morbidity were observed in mice treated with M64 compared to mice that 
received plain DMSO (Figures 9, 10). 
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Figure 9: Kaplan-Meier killing kinetic for 
immunocompromised mice infected intranasally with 
5.75x107 CFUs of AB 5075. Only 30% of untreated mice 
(recieving IV DMSO injections) survived whereas 90% of 
mice given IV M64 in DMSO survived. Analyzed using the 
log-rank test. 
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 In a different lung infection experiment where a different A. baumannii 
strain was being tested, lung tissue was collected from sacrificed mice and 
homogenized into a solution for serial dilution, plating on LB agar, and counting 
lung CFUs as an indicator of the level of infection. This data is shown in Figure 
11. 
Figure 10: Lung index in immunocompromised 
mice three days after intranasal infection with AB 
5075 and treatment with DMSO or M64 in DMSO. 
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Figure 11: Lung bacterial burden four days after infection with ATCC 
17978 in immunocompromised mice with lung infections treated with 
subcutaneous or intravenous 50 µM M64 in DMSO compared to 
controls treated with plain DMSO. Each mouse was infected with 1x109
CFUs at the start. 
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In vitro Experiments 
Effects of M64 on A. baumannii Growth 
 Equally important as figuring out the effects of M64 treatment of A. 
baumannii infection in vivo was the investigation of the effects of M64 on the 
bacterium itself. Figure 12 shows the effects of M64 on the growth of AB 5075 in 
various rich media, and is representative of what was seen in other strains in the 
same media with similar concentrations of M64. 
 Although the strains used in this study exhibited no growth defects in rich 
medium (LB), numerous attempts to grow the strains in M63gcm minimal 
medium exhibited that with the exception of AYE and SDF strains, all other A. 
baumannii strains tested simply will not grow in this medium (Figure 13). 
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Figure 12: Growth of AB 5075 in various rich media in the presence of 
DMSO and 10 µM M64 in DMSO. Negative control (antibiotic) wells exhibited 
flat lines, with no increase from near-zero OD600nm (not shown), indicating 
that the increases in OD600nm in the other wells were due to bacterial 
growth. 
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 Additionally, CFUs were assessed as part of investigating how A. 
baumannii grows in different media in the presence or absence of M64. This data 
is shown in Figure 14, where M64 again shows no effects on A. baumannii 
growth in rich medium but accelerates cell death in the minimal medium. 
 
Figure 13: Growth kinetic of AB5075 in minimal medium M63gcm. The 
failure of this strain to grow in this medium is characteristic of several 
of the A. baumannii strains tested, including ATCC 17978. 
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Figure 14: A. baumannii growth measured in CFU/mL in LB 
(top row) and M63gcm. 
 32 
Knowing that most of the A. baumannii strains could not grow in M63gcm 
and that the only essential amino acid lacking from that medium is tryptophan, 
attempts were made to supplement M63gcm with tryptophan and other 
downstream metabolites to see if growth in the presence of M64 could be 
observed. If growth could be observed in these conditions, it would be strong 
evidence for the target of M64, since the supplemented metabolite would need to 
be downstream of M64 inhibition. No rescue has been observed with any of the 
tested metabolites to date, but other candidates still remain to be tested. The 
data collected to date are summarized in Table 6. 
 
Effects of M64 on A. baumannii Gene Expression 
 LysR-type transcriptional regulators (LTTRs) are a highly abundant and 
thoroughly-studied family of prokaryotic transcriptional regulators that share a 
conserved structure. It was previously discovered that M64 acts on P. aeruginosa 
by inhibiting MvfR, an LTTR important for P. aeruginosa virulence. Such being 
the case, the LTTRs known in A. baumannii provided a good starting point for 
further investigation.  
Table 6: Attempts to grow AB 5075 in supplemented M63gcm and 
circumvent the metabolic interference of M64. 
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Two of the best-studied LTTRs in A. baumannii are the proteins BenM and 
CatM. They are involved as regulators in the pathways of benzoate and catechol 
metabolism respectively, though there may also be cross-regulation that occurs 
(Ezezika et al., 2006). If M64 is inhibiting these LTTRs in A. baumannii, it would 
be expected to see downregulation of their regulons, namely benABCDE and 
catABCIJFD, respectively. To investigate this possibility, RNA was purified from 
A. baumannii grown in the presence of 50 µM M64 in DMSO and cells grown in 
plain DMSO. cDNA was synthesized from the purified RNA and then a qPCR 
assay was done using primers for benM, catM, benAB, and catBC. The results, 
shown in Figure 15, are quite telling.  
First, it is seen that 
transcription levels of BenM and 
CatM in the cells grown in the 
Figure 15: Transcription levels of 
BenM, BenA, BenB, CatM, CatB, 
and CatC in A. baumannii strain 
ATCC 17978 grown to OD600nm 4.0 in 
LB the presence of plain DMSO or 
50 µM M64 in DMSO. 
benA P = 0.017
benB P = 0.088
benM P = 0.670
catB P = 0.198
catC P = 0.12
catM P = 0.512
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presence of M64 are not significantly different from what they are in cells grown 
in the presence of plain DMSO (P = 0.670 and P = 0.512, respectively). Indeed, 
there is a statistically insignificant upwards trend in their transcription levels in the 
treated cells: if anything, this would be consistent with a feedback mechanism 
increasing transcription of these genes in cells where the corresponding protein 
product has been inhibited. The lack of significant decrease in transcription of 
these genes also indicates that M64 is not inhibiting the transcription of some 
other regulator even further upstream from BenM and CatM. 
Although the transcription of these regulators is not affected, M64 could 
interfere with the activity of the BenM and/or CatM proteins. In such a case, one 
would expect a decrease in the levels of transcription of the genes they regulate. 
Indeed, in all of the tested genes, such a downward trend was observed. In the 
case of benA, this trend was statistically significant (P = 0.017) while in other 
genes statistical significance was not quite achieved, but the downward trends 
were still apparent and the levels of significance (P = 0.088 for benB, P = 0.198 
for catB, and P = 0.12 for catC) were much closer to statistical significance than 
what was seen for benM (P = 0.670) and catM (P = 0.512). It seems likely that 
statistical significance could be achieved with a greater number of experimental 
replicates, which should decrease the variability seen in the transcription levels of 
certain genes. This overall result—the four downward trends in the transcription 
of downstream genes combined with no significant change in transcription of 
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their regulators—suggests that M64 is inhibiting the activity of LTTRs BenM and 
CatM. 
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DISCUSSION 
 
 The study began with an investigation into the effects of M64 on the 
growth of A. baumannii strains, while the choices of media used to grow the 
bacteria also seemed to reveal something about the bacteria’s metabolism and 
the possible action of M64. First of all, M64 was not seen to have a significant 
effect on the growth of A. baumannii strains in rich media. The lack of killing and 
growth inhibition in these cases rules out traditional bactericidal or bacteriostatic 
action on the part of M64. 
 Second, most of the A. baumannii strains failed to grow in M63gcm 
minimal medium. Rather than an abject failure, this result actually provided a clue 
about the bacterial metabolism. An important difference between the rich media 
and minimal medium used for these experiments is that, where the rich media 
such as LB contain yeast extract and thus are considered to contain all essential 
amino acids, M63gcm is made with casamino acids. Casamino acids are a nearly 
complete source of amino acids, but lack in tryptophan. 
Thus, the failure of the bacteria to grow in this medium hints at tryptophan 
auxotrophy in these A. baumannii strains. When assessing the CFUs, it was also 
seen that CFUs will diminish over time when most of the A. baumannii strains are 
grown in M63gcm, but they will diminish even faster if grown in M63gcm in the 
presence of M64 (Figure 14). Taken together, these data allowed for rapid 
identification of the putative target(s) of M64.  
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At this time, a clearer picture of the possible overall situation was starting 
to develop: it was known that the bacteria could not grow (and in fact would die 
off) in a medium lacking tryptophan, that this effect was even more profound in 
the presence of M64, and that M64 was previously known to interact with an 
LTTR in P. aeruginosa. These three points focused the next experiments on two 
relatively well-studied LTTRs in A. baumannii that were also known to be 
involved in tryptophan metabolism: BenM and CatM, transcription factors 
involved in the regulation of genes involved in benzoate and catechol metabolism 
respectively (Figure 16). Both of these are metabolites found downstream from 
tryptophan in the tryptophan degradation pathway (overview in Figure 19). 
According to Figure 16, one of the most direct implications that inhibition 
of benABCDE and catABCIJFD transcription may have is a decrease in the 
Figure 16: ben and cat genes and their gene products and their involvement 
in benzoate and catechol metabolism. benABCD, catA, and catBCDIJF gene 
products are enzymes involved in the catabolism of these substances (A). 
BenM and CatM regulate transcription initiation in four regions of the DNA 
(B: diamonds 1 to 4), where the proteins bind to the DNA and activate 
transcription. Adapted from Ezezika et al., 2006. 
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amounts of succinyl-CoA and acetyl-CoA available to the cell. These two 
compounds are important substrates in the citric acid cycle, which means that 
decreasing their availability to the cell could cause a decrease in the availability 
of energy and thus biological stress, a slowing of cell metabolism, or even 
eventual cell death. This concept makes even more sense when considering that 
benzoate and catechol can both be considered downstream products of 
tryptophan metabolism.  A general inability to catabolize an amino acid could 
have many implications for the organism beyond the production of energy, such 
as deficiencies in biosynthesis of other molecules that require downstream 
products of tryptophan metabolism. 
 One such molecule could be the siderophore acinetobactin (Figure 17), 
which facilitates iron acquisition and thus is crucially important in A. baumannii 
growth and virulence (Gaddy et al., 2012), as iron plays a crucial role in cell 
survival and the formation of biofilms (Gentile, 2014). Notably, acinetobactin 
features a catechol moiety, though catechol alone is not itself a siderophore. 
Consequently, a compound that inhibits the cellular metabolism of the catechol 
required to synthesize such a prominent virulence factor would be properly called 
an inhibitor of a virulence factor (or factors) in A. baumannii. As such, with its 
putative inhibitory action on BenM and CatM, M64 is considered as an inhibitor of 
virulence factors in MDR A. baumannii. This is one possible explanation of the 
apparent rescue of infected mice by M64 (Figure 8). 
 39 
Further experiments are required, however, to ascertain the nature of the 
observed inhibitory effects of M64. Although BenM and CatM are known to be 
LTTRs, LTTRs seem to share a conserved domain structure rather than a 
conserved amino acid sequence, as they regulate a remarkably diverse 
collection genes across a great number of bacterial species (Maddocks and 
Oyston, 2008; Figure 18). Thus, although M64 certainly binds to MvfR (Starkey et 
al., 2014), an LTTR in P. aeruginosa, there was never a guarantee that it would 
also bind to BenM or CatM. The data presented here seem to indicate that it 
does, but the proteins should be purified to have their binding affinities for M64 
analyzed. 
Figure 17: Structures of the siderophores acinetobactin (left) and 
anguibactin (produced in Vibrio anguillarum for comparison. The 
catechol moieties are seen at the top of the figure, labelled DHBA 
(dihydroxy benzoic acid). This illustrates the highly conserved 
features of these functionally crucial molecules. Figure adapted 
from McConnell et al., 2013. 
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 The greater statistical significance of the decreased BenA and BenB 
transcription compared to CatB and CatC (Figure 15), for example, may be 
explained by M64 having a higher affinity for binding to BenM than to CatM. It 
may also be that the compound binds to both BenM and CatM with similar 
affinities but that transcription of the benABCDE operon, potentially being 
regulated by both of the LTTRs rather than only one (Ezezika et al., 2006) is 
more strongly inhibited than is transcription of the cat genes. Such cross-
regulation of genes between the two transcription factors may also explain some 
of the difficulty in obtaining statistical significance for their decreased 
transcription levels. 
Figure 18: Amino acid homology in the helix-
turn-helix DNA binding domain of LTTRs in 
various bacterial species. Adapted from 
Maddocks and Oyston, 2008. 
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As for the experiments in vivo, A. baumannii has never been shown to 
exhibit virulence in D. melanogaster in the literature. Repeated infection of wild 
type D. melanogaster with various A. baumannii strains did not produce 
statistically significant levels of fly death, so fly infection modeling was 
abandoned. It may be that Drosophila, especially in comparison to a mouse 
model, is more representative of a minimal nutrient environment than a rich one. 
This would have a similar effect on the bacteria as was seen in their growth in 
M63gcm, and would limit the bacterial ability to able to multiply, infect, and kill 
flies. 
 It was known from the literature, however, that mice are often used to 
model A. baumannii infection, so the next attempt in establishing a model system 
in the lab was to use mice. Although immunocompetent mice did display some 
levels of sickness after A. baumannii infection (even in quantifiable ways—
Figures 6 and 7), the murine immune system generally seemed capable of 
fighting off the infections and no mice succumbed the infections. 
 Mouse death was observed in greater frequencies, however, when using 
relatively high inocula of bacteria to infect immunocompromised mice (Figures 8 
and 9). The immunocompromised mouse was seen not only as a more powerful 
model system where death due to infection could be reliably observed, but also a 
more relevant model of one of the human populations that typically falls victim to 
A. baumannii infection: immunocompromised hospital patients. A now widely-
acknowledged nosocomial pathogen, A. baumannii is increasingly seen as the 
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cause of potentially devastating medical complications that befall vulnerable 
patients who entered the hospital for other reasons, completely unrelated to their 
new infection. The immunocompromised mouse model reflects this patient 
population more accurately than the immunocompetent one. 
 Thus, immunocompromised, neutropenic mice were used to model A. 
baumannii infection and to test the efficacy of M64 in rescuing them. The results 
(Figure 9) were remarkable: mice that otherwise would have likely succumbed to 
their infections (as seen in the control group that received intravenous [IV] 
injections of plain DMSO) were being rescued with several IV injections of 50 µM 
M64. 70% of mice in the control group died within five days, compared to just 
10% of the treated mice. This led to the development of a hypothesis that M64 
was having anti-infective activity in the immunocompromised mice infected with 
A. baumannii. 
Another metric used to compare the two experimental groups, the lung 
index, also proved to be significantly higher in untreated mice than in mice that 
received M64 (Figure 10). As the lung index is defined as the quotient of a 
sacrificed mouse’s right lung weight (mg) divided by the total weight of the mouse 
(g), a mouse with pneumonia, a disease condition which increases the weight of 
the lungs (due to local inflammation) while promoting general weight loss in the 
mouse (due to the stress of disease), should have a relatively high lung index 
compared to a healthy mouse. 
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Since the infected mice treated with M64 proved to have a significantly 
lower lung index than the untreated mice, this seemed to be a second reason to 
believe that M64 was successfully treating bacterial-induced pneumonia in 
immunocompromised mice. The third hit that strongly supported the research 
hypothesis was seen when it was shown that A. baumannii-infected mice treated 
with M64 showed lower levels of lung bacterial burden compared to mice that did 
not receive M64 (Figure 11). 
At the very least, the observations from the in vivo studies in mice seemed 
to demonstrate that M64 was indeed inhibiting virulence factors in A. baumannii. 
In vitro studies ruled out bactericidal or bacteriostatic antibacterial activity while 
implicating some involvement of tryptophan metabolism and BenM and CatM as 
potential targets of the inhibitor. Thus, the improvement seen in mouse survival is 
putatively attributed at least to inhibition of virulence factors, BenM and CatM. 
These proteins are involved in downstream pathways of tryptophan metabolism 
where they regulate production of benzoate and catechol, catechol forming a 
crucial part a siderophore important for Acinetobacter virulence (Figure 19). 
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 To pinpoint the target of M64, however, it would be most useful to 
supplement M63gcm with various metabolites downstream from tryptophan to 
see which ones could promote A. baumannii growth in that medium and also 
which ones could overcome the inhibition exhibited by M64. Tryptophan itself, as 
well as anthranilic acid and benzoic acid, have been tried at various 
concentrations, but none of these supplements were enough to get A. baumannii 
to grow in M63gcm. A deficiency in utilization of these metabolites caused, for 
example, by inability for them to get inside the cells cannot be excluded as a 
possibility, however. Other metabolites, such as kynurenine, 3-hydroxy-
kynurenine, and catechol are soon to be tested. 
 In summary, multidrug resistant A. baumannii continues to present serious 
problems to healthcare professionals and is a major player in the current 
Figure 19: Hypothetical activity of M64 in inhibiting A. baumannii
virulence factors. 
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antibiotic crisis. Traditional antibiotics generally target cellular components that 
are required for bacterial viability or growth. Many infective cells die, but such 
treatments exert selective pressures and fail to eradicate the resistant mutants 
they select for. The infective symptoms perhaps subside but then return, unable 
to be treated with the same antibiotic. To circumvent the direct selective 
pressures of traditional antibiotics that have led to the emergence of multidrug 
resistant strains of bacteria, alternative therapeutic methods should be explored. 
Drugs targeting bacterial virulence factors that are not essential to growth or 
survival have shown some promise in treatment of P. aeruginosa infection by 
inhibition of an LTTR that regulates virulence factors. Demonstrated here is 
evidence of a similar in vitro inhibition by M64 of LTTRs that regulate the 
metabolism of compounds that could be important in energy production and 
virulence in A. baumannii, as well as evidence of the in vivo efficacy of the 
compound in diminishing A. baumannii virulence. The compound does not seem 
to significantly affect bacterial growth. As such, M64 seems to hold some 
promise as a putative treatment in infections by MDR A. baumannii while at the 
same time not exerting the same direct selective pressure of traditional 
antibiotics, making it more difficult for the bacteria to develop a resistance. Such 
treatments are especially desirable given the situation of the current antibiotic 
crisis and could present a new paradigm in the treatment of infectious disease, 
with further study. 
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